Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.79 |
| ▸ | PKM | P14618 | 2/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | ABL1 | P00519 | 1/20 | 0.79 |
| ▸ | LMNA | P02545 | 1/20 | 0.79 |
| ▸ | IDE | P14735 | 1/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.79 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.79 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.79 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.62 |
| ▸ | CA12 | O43570 | 3/20 | 0.62 |
| ▸ | CA1 | P00915 | 3/20 | 0.62 |
| ▸ | CA2 | P00918 | 3/20 | 0.62 |
| ▸ | CA9 | Q16790 | 3/20 | 0.62 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.57 |
| ▸ | PLCD1 | P51178 | 1/20 | 0.57 |
| ▸ | HLCS | P50747 | 1/20 | 0.56 |
| ▸ | F2 | P00734 | 1/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18268949 | 1.00 | TDP1 (0.79) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL12606268 | 0.98 | TDP1 (0.79) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL16913029 | 0.97 | TDP1 (0.77) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL565248 | 0.97 | TDP1 (0.77) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL22975316 | 0.97 | TDP1 (0.77) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL25417015 | 0.97 | TDP1 (0.77) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL10171661 | 0.97 | TDP1 (0.77) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL565479 | 0.97 | TDP1 (0.77) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL12551857 | 0.97 | TDP1 (0.77) | TDP1PKMMEN1ABL1LMNA | |
| SCHEMBL383254 | 0.97 | TDP1 (0.77) | TDP1PKMMEN1ABL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0379949-B1 | Method for the determination of HIV antibodies | BOEHRINGER MANNHEIM GMBH (DE) | 1995-03-29 | — | — | EP | claimed |
| US-5001049-A | Method for determination of HIV specific antibodies | BOEHRINGER MANNHEIM GMBH (DE) | 1991-03-19 | — | — | US | claimed |
| US-20240092737-A1 | SUBSTITUTED SALICYLAMIDE COMPOUNDS AND USE THEREOF | HELIOS HUAMING BIOPHARMA CO., LTD. (CN) | 2024-03-21 | — | — | US | disclosed |
| US-20230381146-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | HELIOS HUAMING BIOPHARMA CO., LTD. (CN) | 2023-11-30 | — | — | US | disclosed |
| US-20230381146-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | HELIOS HUAMING BIOPHARMA CO., LTD. (CN) | 2023-11-30 | — | — | US | disclosed |
| US-20230381146-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | HELIOS HUAMING BIOPHARMA CO., LTD. (CN) | 2023-11-30 | — | — | US | disclosed |
| EP-4277884-A1 | SUBSTITUTED SALICYLAMIDE COMPOUNDS AND USE THEREOF | Helios Huaming Biopharma Co., Ltd. (CN) | 2023-11-22 | — | — | EP | disclosed |
| EP-4225743-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | Helios Huaming Biopharma Co., Ltd. (CN) | 2023-08-16 | — | — | EP | disclosed |
| US-11453640-B2 | Small molecules for disrupting the super elongation complex and inhibiting transcription elongation for cancer therapy | NORTHWESTERN UNIVERSITY (US) | 2022-09-27 | — | — | US | disclosed |
| WO-2022078294-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | HELIOS HUAMING BIOPHARMA CO., LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
| US-5001049-A | Method for determination of HIV specific antibodies | BOEHRINGER MANNHEIM GMBH (DE) | 1991-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11453640-B2 | Small molecules for disrupting the super elongation complex and inhibiting transcription elongation for cancer therapy | SUB1, ELL, MED16 | TDP1 1047/4885PKM 3352/4885MEN1 3866/4885 |
| US-20230381146-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND USE THEREOF | SSB, BTK, PADI6 | TDP1 31/4885PKM 607/4885MEN1 2371/4885 |
| US-20240092737-A1 | SUBSTITUTED SALICYLAMIDE COMPOUNDS AND USE THEREOF | SYMPK, SLC10A2, SLC10A1 | TDP1 1239/4885PKM 2323/4885MEN1 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.